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Summary
Hepatitis B and hepatitis C are contagious liver diseases
caused by the hepatitis B virus (HBV) and the hepatitis
C virus (HCV), respectively. In particular, chronic infec-
tion with HBV or HCV is a major public health problem
throughout Europe. The majority of persons chronically in-
fected (65%–75%) are not aware of their infection status
until symptoms of advanced liver disease appear. In addi-
tion, the peak in the number of patients suffering from ad-
vanced stages of the disease, such as cirrhosis and hepato-
cellular carcinoma, has not yet been reached. In order to
reduce the current and future morbidity and mortality asso-
ciated with chronic HBV or HCV infection, the timely de-
tection of chronically infected persons, with follow-up and
case management, is crucial. However, the current screen-
ing strategies in Europe and Switzerland have to be con-
sidered as inadequate to detect the majority of chronically
infected persons. Hence, we emphasise the importance of
an alternative approach: the healthcare provider initiated
identification of HBV or HCV infection in defined risk
groups. This entails determining whether a person is not
only at risk of being chronically infected, but also at risk
of becoming infected with HBV or HCV and, if necessary,
testing for HBV or HCV infection.
Key words: chronic hepatitis infection; HBV; HCV;
testing; screening; risk groups
Introduction
Hepatitis B and hepatitis C are contagious liver diseases
caused by the hepatitis B virus (HBV) or the hepatitis C
virus (HCV) [1–2]. HBV or HCV infection can be either
acute or chronic. Chronic hepatitis virus infection is a ma-
jor global public health problem, an important cause of
morbidity and mortality from sequelae that include chronic
liver disease and failure, cirrhosis, and hepatocellular car-
cinoma (HCC) [3–5].
Furthermore, chronic liver disease due to coinfection with
HBV or HCV has become a major cause of death in per-
sons infected with the human immunodeficiency virus
(HIV) [3, 6]. Worldwide, about 1 in 12 persons (480–520
million people) are chronically infected with HBV or HCV
[3]. In Europe, about 14 million people are chronically in-
fected with HBV and 9 million people are chronically in-
fected with HCV, compared with 1.5 million infected by
HIV [7]. Chronic viral hepatitis is a silent killer because
of the frequently asymptomatic nature of chronic HBV and
HCV infection. The majority of persons chronically infec-
ted (i.e. 65%–75% of the infected) are not aware of their
infection status until symptoms of advanced liver disease
and failure, cirrhosis and HCC appear [3]. Consequently,
case detection is difficult. Therefore, the timely detection
of chronic hepatitis virus infection, with follow up and case
management, has the potential to contribute significantly to
secondary prevention of chronic hepatitis [8–9].
Although most countries in the European Union (EU) and
Switzerland lack national action plans or national strategies
for the prevention and control of viral hepatitis, different
strategies for identification of chronic HBV and HCV in-
fection are already in place. These include population
screening and healthcare provider initiated testing. The ob-
jective of this review is, on the one hand, to raise awareness
within the primary care community of the public health rel-
evance of chronic hepatitis B and C infection in Switzer-
land and, on the other hand, to advocate the identification
of the chronically infected by using healthcare provider ini-
tiated identification of HBV or HCV infection in defined
risk groups.
Hepatitis B and C
Hepatitis B virus infection
HBV is a partially double-stranded deoxyribonucleic acid
(DNA) virus belonging to the Hepadnaviridae family. The
virus is mainly present in the blood, but is also present in
saliva, semen, vaginal secretions, menstrual blood, any oth-
er body fluid containing blood, and in unfixed tissues and
organs [1, 10].
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Transmission of HBV
Transmission occurs by percutaneous and mucosal expos-
ure to infective body fluids or by maternofoetal transmis-
sion occurring mainly at birth. The presence of the hepatitis
B 'e' antigen (HBeAg) or HBV DNA above 104 copies/ml
indicates high virus titre and higher infectivity of these flu-
ids [11]. Since HBV is stable on environmental surfaces
for at least seven days, indirect inoculation of HBV can
occur via contaminated objects [1]. In areas of high en-
demicity (regions with an HBsAg prevalence of ≥8%), the
most common route of transmission is perinatal, although
the infection may be acquired also during the preschool
years. In areas of intermediate endemicity (HBsAg pre-
valence 2%–7%), transmission is either perinatal or hori-
zontal. In countries of low endemicity (HBsAg prevalen-
ce <2%), most HBV infections are acquired by horizont-
al transmission in adolescent or early adult life, that is,
through unprotected sexual activities [12]. Blood transfu-
sions were once a common route of transmission, but im-
proved diagnostic tests and screening for HBV infection in
blood donations have dramatically reduced the risk of ac-
quiring HBV infection through transfusion [12].
Prevalence of HBV infection in Europe and in Switzerland
According to a review recently conducted by the European
Centre for Disease Prevention and Control (ECDC), the
prevalence data on the hepatitis B surface antigen (HBsAg)
– an indicator of acute and chronic infection and thus for
infectivity – in the general population ranged from 0.1% to
7% by country. Prevalence estimates for HBsAg that were
considered representative were available for these coun-
tries only: Belgium (0.7%), Czech Republic (0.6%), Den-
mark (0.1%), Finland (0.2%), Germany (0.6%), Greece
(2.1%), Ireland (0.1%), Italy (regional and national data
ranged from 0.2%‒4.3%), the Netherlands (0.1%), Ro-
mania (5.6%), Slovakia (0.6%) and Turkey (regional and
national data ranged from 2.5%‒9.0%) [9]. The prevalence
of HBsAg carriers in the general Swiss population is es-
timated to be 0.3% [11]; this means that 23,500 persons in
Switzerland are currently HBV-infected.
In Europe, the HBV prevalence in pregnant women is gen-
erally higher than in the general population and the antenat-
al HBsAg prevalence ranges from 0.1% to 4.4% by country
[9]. In Switzerland, the frequency of HBsAg carriers
among women of child-bearing age is estimated to be 0.7%
[13]. A survey conducted in the year 1999 amongst patients
with renal insufficiency undergoing chronic dialysis treat-
ment in Switzerland revealed a frequency of HBsAg car-
riers of 1.4% [14]. The reported HBsAg prevalence in in-
jection drug users (IDUs) in the EU varied widely, ranging
from 0% in Belgium to 11.6% in Bulgaria in 2006. Gen-
erally, the HBsAg prevalence among IDUs is higher in
countries in Central and Eastern Europe, when compared
with those in Western Europe [9]. A prevalence study in
Switzerland amongst patients with a history of long-term
injection drug use in the years 1994 to 1996 documented
a seroprevalence of the hepatitis B core antigen (HBcAg)
as high as 73.2%, suggesting that the majority of individu-
als were, or had been, in contact with the virus [15]. This
result is in line with the outcome of a review on anti-HBc
seroprevalence in IDUs, which revealed a wide range of
anti-HBc seroprevalence in Europe (4.2%–85.1%) [16]. In
migrants and minority populations in Europe, a wide vari-
ation in HBsAg prevalence was found, ranging from 1.0%
in resident first-generation migrants in the Netherlands up
to 15.4% in Albanian refugees in Greece. However, the
HBsAg prevalence among migrants was in general higher
than in the general population [9].
HBV infection and disease
Only a small proportion of acute HBV infections may be
clinically recognised; fewer than 10% of children and 30%
to 50% of adults with acute HBV infection show icteric
disease [1, 10]. After acute HBV infection, the risk of de-
veloping chronic infection varies inversely with age, being
about 90% in infants infected at birth, 20% to 50% in chil-
dren younger than 5 years, and 1% to 10% in persons in-
fected at a later age [1, 10]. Furthermore, chronic HBV in-
fection is common in persons with immunodeficiency [1].
About one-third of the chronically infected have elevated
aminotransferases; liver biopsy findings range from normal
to severe necroinflammatory hepatitis, with or without cir-
rhosis [1].
However, about 65% of these cases are unaware that they
are chronically infected with HBV [3]. Cirrhosis, liver fail-
ure or HCC will develop in approximately 15% to 40% of
individuals with chronic hepatitis B [12] and an estimated
15% to 25% of these will die prematurely either of cirrhosis
or HCC [1, 3]. Patients with decompensated cirrhosis are
candidates for liver transplantation [12].
The goal of antiviral therapy in chronic HBV infection is to
achieve long-term viral suppression in order to prevent se-
quelae of chronic liver disease, and to reduce viraemia and,
hence, the risk of contagion [5, 11]. Nucleoside and nucle-
otide analogues and pegylated interferon alfa are the most
commonly used antiviral agents in the treatment of chronic
HBV infection [5, 17]. However, current HBV treatments
often do not eradicate HBV, although treatment for one
year generally results in the reduction of serum HBV DNA
to levels undetectable with polymerase chain reaction in up
to 95% of patients. Because responses are not always dur-
able, long-term and often life-long treatment is necessary
to maintain viral suppression and continued clinical benefit
[17].
For primary prevention, safe and effective vaccines against
HBV infection have been available since 1982 [12].
Hepatitis C virus infection
HCV is an enveloped ribonucleic acid (RNA) virus belong-
ing to a separate genus (Hepacivirus) in the Flaviviridae
family and is classified into seven major genotypes with a
broad variety of subtypes [18]. The distribution of geno-
types varies geographically. In Europe, HCV genotypes 1
and 3 are most prevalent, and genotype 2 is commonly en-
countered in the Mediterranean area [5].
Transmission of HCV
HCV is efficiently transmitted via direct percutaneous ex-
posure to infectious blood [5]. Depending on the viral load,
HCV may be present in other body fluids such as saliva,
sweat, tears or semen [19]. It was shown by using tissue
culture assays that HCV is stable and may remain infective
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on environmental surfaces for several days. Hence, indirect
inoculation of HCV can occur via contaminated objects
[20]. Hepatitis C became a global epidemic in the 20th
century as blood transfusions, haemodialysis and the use
of injection needles to administer licit and illicit drugs in-
creased throughout the world. The identification of the vir-
us in 1989 led to measures to reduce healthcare-related ex-
posure to HCV. With this reduction and the introduction
of routine testing of donated blood, HCV infection through
injection drug use (and intranasal drug use with the com-
mon use of utensils) has become the major source of expos-
ure to HCV, and the primary mode of HCV transmission in
Europe and in the US [3, 19]. Mother-to-child transmission
has been documented, but appears rare [2]. Sexual trans-
mission of HCV occurs infrequently. However, there seems
to be a relevant and increasing risk of sexual transmis-
sion within certain populations, for example, among men
who have sex with men (MSM), especially when coinfec-
ted with HIV, or among persons with high-risk sexual be-
haviour [19, 21–22].
Prevalence of HCV infection in Europe and in Switzerland
The anti-HCV prevalence (as an indicator of past or current
HCV infection) in the general population in Europe ranges
from 0.4% to 3.5% by country and from 0.2% to 10.4% by
region within certain countries (especially Italy). Prevalen-
ce estimates that are considered representative were avail-
able for only three countries: the Czech Republic (0.2%),
Germany (0.4%) and Romania (3.5%) [9]. Anti-HCV pre-
valence in the Swiss population, based on studies in sub-
populations in the 1990s, is estimated to be between 0.7%
and 1.0% [11]. Hence, between 55,000 and 78,000 persons
in the general Swiss population are currently HCV-infec-
ted. However, the true anti-HCV prevalence in the general
population of Switzerland might be up to 1.3% to 1.8%, as
reported in a mathematical modelling study [23–24].
In Europe, the overall prevalence of anti-HCV is much
higher than the HBsAg prevalence among IDUs and ranged
from 30% to 98%, with a great variation within the differ-
ent European countries [9]. Based on studies in the years
1994 to 1996, the anti-HCV prevalence rates in IDUs in
Switzerland ranged from 56.4% to 82.2% [15, 25]. The
anti-HCV prevalence in pregnant women in Europe ranges
from 0% to 1.7% by country [9], and in Switzerland it was
estimated to be 0.7% [26]. The prevalence of anti-HCV
among migrants and minority populations of European
countries ranges widely from 0% to 23.4% [9]. A survey
amongst patients undergoing chronic dialysis treatment in
Switzerland in 1999 found an anti-HCV prevalence of
5.1% [14].
HCV infection and disease
Only 25% of HCV-infected persons will develop acute hep-
atitis with jaundice or have elevated aminotransferases [19,
27]. The remaining 75% of HCV-infected persons exhibit
no, or only nonspecific, clinical signs [19]. In contrast to
HBV, 50% to 85% of infected adult persons will develop
chronic HCV infection [5, 19]. Overall, 10% to 20% of pa-
tients with chronic HCV hepatitis will develop complica-
tions of chronic liver disease, such as cirrhosis, within two
to three decades of onset, and 1% to 5% will develop HCC
[28]. By 2007, HCV had surpassed HIV as a cause of death
in the US [29]. Nevertheless, an estimated 75% of the in-
fected people are unaware of their HCV infection [3].
Antiviral therapy with pegylated interferon alfa in combin-
ation with ribavirin was, until very recently, the gold stand-
ard for the treatment of hepatitis C [5]. However, with this
regimen, the permanent eradication of HCV occurs in only
one-half of the patients [5] and in fewer than 50% of pa-
tients infected with genotype 1 [30]. New antiviral agents
specifically targeting the NS3/4a protease are potent inhib-
itors of HCV replication and can result in rapid declines in
serum HCV RNA levels [30]. Clinical trials showed that in
HCV genotype 1, treatment-naive HCV adult patients, the
antiviral drug telaprevir in combination with pegylated in-
terferon alfa and ribavirin can result in rates of sustained
virological response (SVR; defined as undetectable HCV
RNA in serum 24 weeks after the end of therapy) as high
as 75% [31]. Treatment with the antiviral boceprevir in the
same patient group resulted in SVR rates as high as 68%
[32]. For the very first time, the newly achievable SVR
rates of 68% to 75% in patients infected with HCV geno-
type 1 [31–32] reach the SVR rates of 65% to 82% in pa-
tients infected with HCV genotypes 2 and 3 after stand-
ard treatment with pegylated interferon alfa in combination
with ribavirin [33]. Achievement of SVR potentially halts
fibrosis progression, prolongs survival and decreases the
risk of HCC or end-stage liver disease. In 2011, bocepre-
vir and telaprevir have been approved in the EU and in
Switzerland under special treatment conditions.
Although there is a clear need for a preventive vaccine and
research in this field is ongoing, to date a safe and efficient
vaccine against HCV does not exist [34].
Future challenges of HBV and HCV infection
It is impossible to predict with certainty the future epidemi-
ological and clinical developments of hepatitis infection
and disease. However, the worldwide peak in the number
of patients suffering from cirrhosis and cancer, or of those
waiting for a life-saving liver transplant, has not yet been
reached, as many of those chronically infected with HBV
or HCV (who acquired their infection two to three decades
ago) have not yet reached the advanced stages of the dis-
ease. In the US, the extent of HBV and HCV infection have
already reached epidemic proportions [29] and the World
Health Organisation (WHO) compared HCV infection to a
“viral time bomb” [35–36].
International assessments of the future situation of viral
hepatitis may shed some light on the future development
in Europe and in Switzerland. As an example, in the UK,
the prevalence of chronic hepatitis B has increased dramat-
ically from 150,000 to an estimated 325,000 persons, with
a significant contribution from immigration from areas of
high endemicity, such as Eastern Europe and Africa, within
the period 2004 to 2008. Current migration figures suggest
that the number of chronically HBV-infected cases in the
UK will keep on rising in the near future, and that most of
the existing and newly arrived cases remain undiagnosed
[37]. In contrast, the prevalence of chronic hepatitis C in
the UK remains quite stable at an estimated level of 0.5%
to 0.7% (i.e. 250,000–350,000 persons). It is assumed that
this silent pool of HCV infection, if left unidentified and
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untreated, will result in a significant burden of advanced
liver disease cases over the next 20 to 30 years. Given that
young adults are infected with HCV (laboratory reports
between 1995 and 2010 in England showed that 49% were
in individuals aged between 25 and 39 years) these time in-
tervals are clinically relevant [37–38]. It is predicted that
the number of individuals in England developing HCV-re-
lated cirrhosis will double between 2005 and 2015 with a
parallel increase in the incidence of decompensated liver
disease and HCC, if left untreated [37, 39]. Cirrhosis of any
cause and HBV infection are already responsible for the
overwhelming majority of cases of HCC in the UK. An in-
crease in the incidence of cirrhosis will be paralleled by an
increase in the incidence of HCC in a few years from now
[37].
Regarding HCV infection, the main effort in global HCV
care (besides developing highly efficient and well-tolerated
HCV compounds) should focus on overcoming barriers to
HCV testing, assessment and therapy, especially in margin-
alised, but highly affected, populations like IDUs and mi-
grants.
Identification of persons with chronic
HBV or HCV infection
The main goals of the identification of chronically infected
persons are to reduce the morbidity and mortality asso-
ciated with cirrhosis and HCC [3]. There are different
strategies for the identification of persons with chronic
HBV or HCV infection. Besides voluntary testing reques-
ted by the person concerned (which is tackled by education
and empowerment measures), two different strategies exist
for identifying persons with HBV or HCV infection: pop-
ulation screening and healthcare provider initiated testing
based on identified risk-factors in patients [3, 40–41].
Population screening
Population screening is a strategy used to detect HBV or
HCV infection in asymptomatic individuals, enabling earli-
er intervention and management to reduce morbidity and
mortality. However, the costs of screening (including dia-
gnosis, medical management and, if appropriate, treatment)
should be economically balanced in relation to possible ex-
penditure on medical care as a whole [42]. Screening the
general population for HBV or HCV is very unlikely to
be cost-effective, for one reason because of the low pre-
valence of infection in the general population [41, 43–45].
Table 1: Populations at risk of hepatitis B virus (HBV) infection.
A. Clinical signs or symptoms of hepatitis
Persons with elevated liver enzymes (transaminases)
Persons with clinical signs or symptoms of hepatitis
Patients with liver cirrhosis, fibrosis or hepatocellular carcinoma
B. Risk factors
Medical
Persons who have chronic liver disease
Persons who are undergoing or have undergone haemodialysis
Persons with HIV or other sexually transmitted infections
Persons with HCV infection
Patients before or during immunosuppressive treatment or chemotherapy
Recipients of organ transplants and blood products
Demographic
Persons and migrants born or having lived during childhood in geographic regions with HBsAg prevalence ≥2%
Persons and migrants visiting their relatives in geographic regions with HBsAg prevalence ≥2%
Behavioural
Families and household members of persons infected with HBV
Sexual partners of persons infected with HBV
Heterosexual persons with multiple sex partners
Men who have sex with men
People who inject or have ever injected drugs (injection drug users)
Long-stay travellers with contact with the local population in geographic regions with HBsAg prevalence ≥2%
Occupational
Healthcare workers at risk for occupational exposure to blood or blood-contaminated body fluids
Healthcare workers after exposure to blood or blood-contaminated body fluids (e.g. needlestick injury)
Public-safety workers at risk of occupational exposure to blood or blood-contaminated body fluids
Staff in psychiatric institutions or residents of welfare institutions for mentally disabled persons
Others
Newborns of HBV-infected mothers
Patients in psychiatric institutions or residents of welfare institutions for mentally disabled persons
Persons with imprisonment history
Persons with body piercings or tattoos if performed in poor hygienic environments
Victims of rape
Persons with accidental needlestick injury in public places (e.g. park or street)
From references [3, 11, 50, 55, 58], modified.
HBsAg = hepatitis B virus surface antigen, HCV = hepatitis C virus; HIV = human immunodeficiency virus.
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Therefore, targeted screening, that is, screening defined
populations with a high risk of HBV or HCV exposure and
pregnant women (to prevent perinatal transmission of HBV
only), is an adequate strategy [3, 46–49]. Screening high-
risk populations is already done throughout the European
region [9].
In the EU and in Switzerland, there are no national policies
for screening for HBV in migrants [9]. However, antenatal
screening is widely conducted throughout the EU member
states and in Switzerland [9, 50]. Screening for both HBV
and HCV infection in blood donations is conducted
throughout the EU and in Switzerland [9, 51]. On the other
hand, HCV screening during pregnancy is not recommen-
ded, since the risk of vertical transmission of HCV is low
and currently not reducible, and a treatment for infants is
not available [43, 46]. Apart from a range of professional
consensus statements which support screening for HCV in
IDUs, there are currently no screening policies for HCV in
IDUs implemented in the EU and in Switzerland [9].
In the US, HCV infection is most prevalent among adults
born between 1945 and 1965 [52]. A large proportion of
these persons probably acquired their infection from activ-
ities related to injection drug use in the 1960s and 1970s
[53]. Consequently, the existing US strategies for the iden-
tification of HCV infection were amended in 2012 by im-
plementation of HCV screening of all adults born during
1945 to 1965 (“birth-cohort screening”) [54].
Healthcare provider initiated testing
The current screening strategies in Europe and in Switzer-
land cover only antenatal screening for HBV infection in
pregnant women and screening for HBV or HCV infection
in blood donations. Hence these screening strategies have
to be considered as insufficient for identifying other indi-
viduals at high risk of HBV or HCV infection, who be-
long to other subpopulations and who form the majority
of chronically infected persons. Hence, the healthcare pro-
vider initiated identification of HBV or HCV infection
among defined risk groups is a valuable instrument in sec-
ondary prevention [55]. This approach entails a (primary)
healthcare provider determining whether a person is not
only at risk for being chronically infected, but also at risk
of becoming infected with HBV or HCV, by reviewing
the patient’s history and, if necessary, testing for HBV
or HCV infection. A greater variety of risk factors than
those covered by the screening strategies in place, such as
demographic, behavioural, occupational and medical risk
factors, and clinical signs or symptoms of hepatitis, may
serve as such indicators [3].
Consequently, persons with chronic HBV or HCV infection
should be referred for medical care and case-management,
and persons found to have risk factors for HBV or HCV in-
fection should receive counselling about prevention (those
at risk for becoming infected with HBV should be addition-
ally offered vaccination) [3].
In the US, this approach has been presented as a key
concept for the prevention and control of hepatitis B and
C in the national strategy published in 2010 [3]. Outside
the US, a similar identification process for chronic HBV
and HCV infection was implemented in the national action
plan of France (Plan national de lutte contre les Hépatites
B et C, 2009–2012) [56]. In Ireland, the risk-factor-based
approach for the identification of chronic infection was im-
plemented in the national strategy to control HCV infec-
tion (National Hepatitis C Strategy 2011–2014) [57]. In
2009, an European expert group including, amongst oth-
ers, members of the European Liver Patients Association
(ELPA), the European Association for the Study of the
Liver (EASL), the Institut de Veille Sanitaire (InVS), the
French Ministry for Health and Sports, Health Protection
Scotland, and the European Monitoring Centre for Drugs
and Drug Addiction (EMCDDA), published a document
with recommendations for the promotion of healthcare pro-
vider initiated testing for HBV and HCV infection [55].
In Switzerland, up to now there were limited recommend-
ations regarding risk-factor based identification of HBV
infection. In contrast, the risk-factor based identification
approach for HCV infection has been recommended in
Switzerland since 1993 [50, 58–59]. Hence, broadening the
already existing risk-factor based identification approach
for HCV and transferring this procedure to the identifica-
tion of HBV infection in Switzerland is suggested. Further-
more, awareness of this identification procedure amongst
the Swiss primary care community should be raised as it is
they who are asked to implement the health-care provider
initiated identification of HBV or HCV infection among
defined risk groups in their day-to-day work with patients.
This publication is intended to provide a base for further in-
formation for the healthcare community.
A consensus on the identified risk factors for chronic infec-
tion or for becoming infected with HBV or HCV, such as
demographic, behavioural, occupational and medical risk
factors, and clinical signs or symptoms of hepatitis are
summarised in tables 1 and 2. These tables should serve as
guidance for identifying persons belonging to these at-risk
populations. These persons should have their history re-
viewed by a (primary) healthcare provider, should be con-
sidered for testing for HBV or HCV infection and, if war-
ranted, referred for medical care and case management.
Testing for HBV or HCV infection
Figure 1
Testing for chronic hepatitis B virus (HBV) infection: absence of
anti-HBc excludes HBV infection, while the presence of HBsAg
indicates ongoing infection.
Anti-HBc = antibody to hepatitis B core antigen; Anti-HBe =
antibody to hepatitis B ‘e’ antigen, HBeAg = hepatitis B ‘e’ antigen;
HBsAg = hepatitis B surface antigen; HBV DNA = HBV
deoxyribonucleic acid.
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Testing for HBV infection
Detection of specific HBV antigens or antibodies in serum
confirms the diagnosis. Three clinically useful antigen-an-
tibody systems have been identified for HBV: the HBsAg
and antibody to HBsAg (anti-HBs); the HBcAg and anti-
body to HBcAg (anti-HBc); and the HBeAg and antibody
to HBeAg (anti-HBe). Commercial kits are available for
all markers except HBcAg. The serological markers can be
used to identify the different phases of HBV infection. The
preferred laboratory test for detecting current HBV infec-
Table 2: At-risk populations for hepatitis C virus (HCV) infection.
A. Clinical signs or symptoms of hepatitis
Persons with elevated liver enzymes (transaminases)
Persons with clinical signs or symptoms of hepatitis
Patients with liver cirrhosis, fibrosis or hepatocellular carcinoma
B. Risk factors
Medical
Recipients of clotting-factor concentrates and blood products before 1987
Recipients of blood transfusions before July 1992
Recipients of solid-organ transplants before July 1992
Patients who are undergoing or have undergone haemodialysis
Persons with HIV infection
Persons with HBV infection
Persons who have received repeated percutaneous injections
Persons who have had invasive medical and paramedical or dental work in settings with high prevalence or poor infection control practices
Demographic
Persons and migrants born or having lived in regions of high HCV endemicity
Behavioural
Persons who inject or have ever injected drugs (injection drug users)
Persons who use or have ever used intranasal drugs
Men who have sex with men
Household members or sexual partners of persons with HCV infection
Occupational
Healthcare workers at risk for occupational exposure to blood or blood-contaminated body fluids
Healthcare workers after exposure to blood or blood-contaminated body fluids (e.g. needlestick injury)
Public-safety workers at risk for occupational exposure to blood or blood-contaminated body fluids
Others
Persons with imprisonment history
Persons with body piercings or tattoos if being performed in poor hygienic environments
Children of HCV-infected mothers
Persons with accidental needlestick injury in public places (e.g. park or street)
From references [3, 11, 55, 58], modified.
HBV = hepatitis B virus; HIV = human immunodeficiency virus.
Table 3: Interpretation of hepatitis B serological diagnostic test results [3].
Antigen or antibody Test Result Interpretation
HBsAg
Anti-HBc
Anti-HBs
All negative Susceptible
HBsAg
Anti-HBc
Anti-HBs
Negative
Positive
Positive
Immune because of natural infection
HBsAg
Anti-HBc
Anti-HBs
Negative
Negative
Positive
Immune because of hepatitis B vaccination
HBsAg
Anti-HBc
IgM anti-HBc
Anti-HBs
Positive
Positive
Positive
Negative
Acutely infected
or
Reactivation (low titre of IgM anti-HBc)
HBsAg
Anti-HBc
IgM anti-HBc
Anti-HBs
Positive
Positive
Negative
Negative
Chronically infected
HBsAg
Anti-HBc
Anti-HBs
Negative
Positive
Negative
Interpretation unclear; could be due to
Resolved infection
False-positive anti-HBc test
Low-level chronic infection
Resolving acute infection
HBsAg = hepatitis B surface antigen; anti-HBc = total hepatitis B core antibody; anti-HBs = hepatitis B surface antibody; IgM anti-HBc = immunoglobulin M antibody to
hepatitis B core antigen.
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tion is HBsAg, which can be detected in serum from sever-
al weeks before onset of symptoms to days, weeks, months
or years after onset. The presence of HBsAg indicates that
the person is infectious. The principal test for detecting re-
covery from HBV infection is anti-HBs as outlined in fig-
ure 1 and also shown in the annex. An alternative is to
test initially for anti-HBc – which is present during acute,
chronic, and resolved HBV infection – and, if the res-
ult is positive, to conduct follow-up testing for HBsAg
and anti-HBs [3]. The IgM antibody to HBcAg (immun-
oglobulin (Ig) M anti-HBc) usually disappears within 6
months but may reappear at low titres if hepatitis react-
ivates with chronic hepatitis; nonetheless, this test may
reliably diagnose acute HBV infection. The presence of
HBeAg is associated with relatively high infectivity [1, 3].
Unfortunately, HBV markers can be misinterpreted, and
this can lead to clinical errors in patient evaluation, coun-
selling or treatment. Table 3 summarises the interpretation
of HBV serological diagnostic test results. The detection of
Figure 2
Testing for acute hepatitis C virus (HCV) infection after exposure: in
the acute phase of infection HCV ribonucleic acid (RNA) becomes
detectable before anti-HCV. A suspected acute HCV infection must
be investigated by means of a HCV RNA test.
Figure 3
Testing for chronichepatitis C virus (HCV) infection: chronic HCV
infection is defined as two consecutive positive HCV ribonucleic
acid (RNA) tests at intervals of at least 6 months.
IDU = intravenous drug user.
HBV DNA in blood serum with nucleic acid amplification
techniques, such as the polymerase chain reaction (PCR),
can be used as a marker for hepatitis B viraemia and hence
may serve as a measure of infectivity [10].
Testing for HCV infection
Diagnosis depends on detecting HCV antibody (anti-
HCV). Various tests are available for the diagnosis and
monitoring of HCV infection. Tests that detect antibodies
against the virus include the enzyme immunoassay (EIA)
and the recombinant immunoblot assay. The same HCV an-
tigens are used in both EIAs and the immunoblot assays.
These tests do not distinguish between acute, chronic or re-
solved infection. EIA tests for the diagnosis of HCV are
suitable for screening at-risk populations. A negative EIA
test is enough to exclude a diagnosis of chronic HCV in-
fection in immunocompetent patients. The high sensitivity
and specificity of the current EIAs obviate the need for a
confirmatory immunoblot assay in the diagnosis of indi-
viduals with clinical liver disease, particularly those with
risk factors for HCV. Immunoblot assays may be useful as
a supplemental assay in persons with a positive EIA who
test negative for HCV RNA. Acute or chronic HCV infec-
tion in a patient with a positive EIA test should be con-
firmed by detection of the presence of HCV RNA in the
serum. A single positive assay for HCV RNA confirms act-
ive HCV replication, but a single negative assay does not
exclude viraemia and may reflect a transient decline in vir-
al level below the level of detection of the assay. There-
fore, a follow-up HCV RNA assay should be performed to
confirm the absence of active HCV replication. Quantitat-
ive determination of HCV RNA levels and of HCV geno-
type provides information on the likelihood of response to
treatment in patients undergoing antiviral therapy [2]. See
figures 2 and 3 and also the annex for testing procedures
for acute and chronic HCV infection.
What to do after a positive test for HBV or HCV
infection
As indicated above, the presence of chronic hepatitis B or
C infection may lead to cirrhosis, end-stage liver disease or
HCC and, ultimately, to death. Therefore, persons found to
be positive for either one or both of these infections need
to be carefully investigated in order to determine whether
they will benefit from medical care and case management,
often comprising antiviral treatment or liver transplantation
(rarely). Consequently, these persons should be referred to
a liver specialist who will confirm the HBV or HCV infec-
tion, evaluate the liver status using appropriate procedures,
often including a liver biopsy to assess the severity of the
liver injury and to exclude the presence of HCC. Initiat-
ing life-saving anti-viral treatment for HBV or HCV infec-
tion needs to be evaluated carefully. The appropriate drug
regimen is subject to constant improvements in the choice
of drug combinations, treatment schedule and outcome de-
termination, emphasising the need for a case management
by an experienced liver specialist without delay.
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Annex
Evolution of HBV infection and overview of testing for
HBV or HCV infection
After the diagnosis of chronic HBV infection has been es-
tablished, the infection is characterized by a first phase of
immunotolerance (particularly in newborns and children)
with high or very high viraemia (HBV DNA) and nor-
mal or quasi-normal transaminases. In this phase, HBeAg
is detectable. As a consequence of an immunoreaction,
the second phase of chronic hepatitis B infection, the im-
mune clearance phase, develops, with elevated transam-
inases, detectable HBeAg and elevated HBV DNA levels.
In this phase significant progression of fibrosis may occur
and mutant forms of the virus may develop. During the
third phase, the inactive HBsAg carrier phase, transam-
inases are normal and the viral replication is low. This
phase coincides with seroconversion of HBeAg and emer-
gence of anti-HBe. In some patients the only serological
feature of an HBV infection is the presence of anti-HBc
antibodies. Seroconversion of HBsAg to anti-HBs leads to
resolution of HBV infection. However, some individuals
may undergo reactivation into a fourth phase known as
HBeAg-negative chronic HBV, where transaminases and
HBV DNA may fluctuate over time.
Addresses of liver centres in Switzerland
Addresses of liver centres.
Basel
Abteilung für Gastroenterologie und Hepatologie
Universitätsspital Basel
Petersgraben 4
4031 Basel
Bern
Universitätsklinik für Viszerale Chirurgie und Medizin
Inselspital
3010 Bern
Genève
Service de Gastroentérologie et d’Hépatologie
Hôpitaux Universitaires
4 rue Gabrielle-Perret-Gentil
1211 Genève 14
Lausanne
Service de Gastroentérologie et Hépatologie CHUV
Rue du Bugnon 44
1011 Lausanne
Centre Saint-Martin
Rue Saint-Martin 7
1003 Lausanne
Lugano
Centro di Epatologia
Clinica Luganese Moncucco
Via Moncucco 10
6900 Lugano
Neuchâtel
Consultation de Maladies Inféctieuses
Département de Médecine
Hôpital Pourtalès
2002 Neuchâtel
St. Gallen
Fachbereich Gastroenterologie/Hepatologie
Kantonsspital
9007 St. Gallen
Zürich
Abteilung für Gastroenterologie und Hepatologie
Universitätsspital Zürich
Rämistrasse 100
8091 Zürich
Hepatitis centres for people who use drugs.
Basel
Zentrum für Suchtmedizin ZfS
Haltingerstrasse 65
4057 Basel
Genève
Unité des Dépendances
Département de Médecine Communautaire
Hôpital Cantonal
4 Rue Gabrielle-Perret-Gentil
1211 Genève
Zürich
Arud, Zentren für Suchtmedizin
Konradstrasse 32
8005 Zürich
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Figures (large format)
Figure 1
Testing for chronic hepatitis B virus (HBV) infection: absence of anti-HBc excludes HBV infection, while the presence of HBsAg indicates
ongoing infection.
Anti-HBc = antibody to hepatitis B core antigen; Anti-HBe = antibody to hepatitis B ‘e’ antigen, HBeAg = hepatitis B ‘e’ antigen; HBsAg =
hepatitis B surface antigen; HBV DNA = HBV deoxyribonucleic acid.
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Figure 2
Testing for acute hepatitis C virus (HCV) infection after exposure: in the acute phase of infection HCV ribonucleic acid (RNA) becomes
detectable before anti-HCV. A suspected acute HCV infection must be investigated by means of a HCV RNA test.
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Figure 3
Testing for chronichepatitis C virus (HCV) infection: chronic HCV infection is defined as two consecutive positive HCV ribonucleic acid (RNA)
tests at intervals of 6 month ■■in minimum■■.
IDU = intravenous drug user.
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